Understanding the role of a specific protein in Alzheimer's disease
Deteriming the Role of Caspase Cleaved Tau in Alzheimer’s Disease
This study is looking at a protein called tau that changes in Alzheimer's disease to see if a specific type of it is harmful or just a reaction to the illness, with the hope that understanding this could help find better ways to treat or manage Alzheimer's for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10868742 on NIH RePORTER |
What this research studies
This research investigates how a protein called tau, which is altered in Alzheimer's disease, may contribute to the progression of the condition. The study focuses on a specific form of tau that is cleaved by enzymes known as caspases, exploring whether this process is harmful or a response to the disease. By examining the effects of inhibiting these enzymes in laboratory models, the research aims to clarify their role in Alzheimer's pathology and identify potential therapeutic targets. Patients may benefit from insights gained about how to better manage or treat Alzheimer's disease based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk for developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that target tau pathology in Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting tau pathology, suggesting that this approach may lead to significant advancements in Alzheimer's treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ambrose, Andrew J — University of California, San Francisco
- Study coordinator: Ambrose, Andrew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.